| Bioactivity | TGFBR1-IN-1 is an ALK5 inhibitor extracted from patent WO2018004290A1, Compound 33, has an IC50 of 10-100 nM[1]. |
| Invitro | Transforming Growth Factor-β (TGF-β) signaling regulates various cellular responses such as cell proliferation, differentiation, cell migration and cell death. TGF-β has at least three isoforms TGF-β1, TGF-β2 and TGF-β3. TGF-β1 is two well-conserved single membrane serine/threonine kinase type I (ALK5). ALK5 inhibitos can be used for treating fibrotic disease, tumor, inflammatory disease, and autoimmune disease[1]. |
| Name | TGFBR1-IN-1 |
| CAS | 2170830-26-7 |
| Formula | C23H17N5O2S |
| Molar Mass | 427.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Novel pyrazole derivative as alk5 inhibitor and uses thereof. WO2018004290A1. |